Scientists dive deep into Epcoritamab's effects on Hard-to-Treat blood cancers
NCT ID NCT06676033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood, lymph node, and bone marrow samples from 5 people with chronic lymphocytic leukemia or Richter syndrome who are receiving the drug epcoritamab. Researchers want to understand how the drug changes immune cells and tumor cells over time. The goal is to learn more about how this type of immunotherapy works, which could lead to better treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
epcoritamab
What this could lead to
If successful, this study could reveal how epcoritamab attacks cancer cells, helping to improve future treatments for CLL and Richter syndrome.
What could go wrong
This is a very small, early-phase study with only 5 participants, focused on lab analysis rather than direct treatment outcomes. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States